Cucurbitacin BCAS# 6199-67-3 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 6199-67-3 | SDF | Download SDF |
| PubChem ID | 5281316 | Appearance | White powder |
| Formula | C32H46O8 | M.Wt | 558.70 |
| Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
| Synonyms | Amarine | ||
| Solubility | DMSO : ≥ 100 mg/mL (178.99 mM) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | [(E,6R)-6-[(2S,8S,9R,10R,13R,14S,16R,17R)-2,16-dihydroxy-4,4,9,13,14-pentamethyl-3,11-dioxo-2,7,8,10,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl] acetate | ||
| SMILES | CC(=O)OC(C)(C)C=CC(=O)C(C)(C1C(CC2(C1(CC(=O)C3(C2CC=C4C3CC(C(=O)C4(C)C)O)C)C)C)O)O | ||
| Standard InChIKey | IXQKXEUSCPEQRD-DKRGWESNSA-N | ||
| Standard InChI | InChI=1S/C32H46O8/c1-17(33)40-27(2,3)13-12-23(36)32(9,39)25-21(35)15-29(6)22-11-10-18-19(14-20(34)26(38)28(18,4)5)31(22,8)24(37)16-30(25,29)7/h10,12-13,19-22,25,34-35,39H,11,14-16H2,1-9H3/b13-12+/t19-,20+,21-,22+,25+,29+,30-,31+,32+/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Cucurbitacin B, an effective HIF-1 inhibitor, has antitumor activity, it inhibits proliferation and induces apoptosis via STAT3 pathway inhibition in A549 lung cancer cells. It inhibited AKT signaling activation through up-regulation of PTEN. |
| Targets | PKA | cAMP | HIF | mTOR | Akt | ERK | JAK | STAT | p53 |
| In vitro | Cucurbitacin B inhibits neuroblastoma cell proliferation through up-regulation of PTEN.[Pubmed: 25487942]Eur Rev Med Pharmacol Sci. 2014;18(21):3297-303.Cucurbitacins belong to a class of highly oxidized tetracyclic triterpenoids. Recent studies suggest that the use of Cucurbitacin could repress cancer cell progression. However, the biological effect of Cucurbitacin-B in neuroblastoma cells remains unexplored.
VASP activation via the Gα13/RhoA/PKA pathway mediates cucurbitacin-B-induced actin aggregation and cofilin-actin rod formation.[Pubmed: 24691407]PLoS One. 2014 Apr 1;9(4):e93547.Cucurbitacin B (CuB), a potent antineoplastic agent of cucurbitacin triterpenoids, induces rapid disruption of actin cytoskeleton and aberrant cell cycle inhibiting carcinogenesis. However, the underlying molecular mechanism of such anticancer effects remains incompletely understood.
|
| In vivo | Cucurbitacin B inhibits the translational expression of hypoxia-inducible factor-1α.[Pubmed: 24333213]Eur J Pharmacol. 2014 Jan 15;723:46-54.Cucurbitacin B is a triterpenoid compound isolated from Trichosanthes kirilowii Maximowicz, which has been used in oriental medicine for its antitumor activities. However, the mechanisms by which Cucurbitacin B inhibits tumor growth are not fully understood.
|
| Kinase Assay | Cucurbitacin B regulates immature myeloid cell differentiation and enhances antitumor immunity in patients with lung cancer.[Pubmed: 22746287 ]Cancer Biother Radiopharm. 2012 Oct;27(8):495-503.The aberrant activation of the JAK2/STAT3 signaling in immature myeloid dendritic cells (DCs) is associated with immune tolerance and poor antitumor immunity.
|
| Cell Research | Cucurbitacin B markedly inhibits growth and rapidly affects the cytoskeleton in glioblastoma multiforme.[Pubmed: 18561312]Int J Cancer. 2008 Sep 15;123(6):1364-75.Cell lines:U87, T98G, U118, U343, and U373 cells |
Cucurbitacin B Dilution Calculator
Cucurbitacin B Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.7899 mL | 8.9493 mL | 17.8987 mL | 35.7974 mL | 44.7467 mL |
| 5 mM | 0.358 mL | 1.7899 mL | 3.5797 mL | 7.1595 mL | 8.9493 mL |
| 10 mM | 0.179 mL | 0.8949 mL | 1.7899 mL | 3.5797 mL | 4.4747 mL |
| 50 mM | 0.0358 mL | 0.179 mL | 0.358 mL | 0.7159 mL | 0.8949 mL |
| 100 mM | 0.0179 mL | 0.0895 mL | 0.179 mL | 0.358 mL | 0.4475 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Cucurbitacin B belongs to a class of highly oxidized tetracyclic triterpenoids; could repress cancer cell progression. IC50 value: Target: anticancer natural compound in vitro: Cucurbitacin-B inhibited growth and modulated expression of cell-cycle regulators in SHSY5Y cells. At the molecular level, we found that Cucurbitacin-B inhibited AKT signaling activation through up-regulation of PTEN [1]. CuB induced apoptosis of A549 cells in a -concentration-dependent manner, as determined by fluorescence microscopy, flow cytometry and transmission electron microscopy. CuB dose-dependently inhibited lung cancer cell proliferation, with cell cycle inhibition and cyclin B1 downregulation. Apoptosis induced by CuB was shown to be associated with cytochrome c release, B-cell lymphoma 2 downregulation and signal transducer and activator of transcription 3 pathway inhibition [2]. CuB inhibited ITGA6 and ITGB4 (integrin α6 and integrin β4), which are overexpressed in breast cancer. Furthermore, CuB also induced the expression of major ITGB1and ITGB3, which are known to cause integrin-mediated cell death [3]. Cuc B treatment caused DNA double-strand breaks (DSBs) without affecting the signal transducer and activator of transcription 3 (STAT3), the potential molecular target for Cuc B. Cuc B triggers ATM-activated Chk1-Cdc25C-Cdk1, which could be reversed by both ATM siRNA and Chk1 siRNA. Cuc B also triggers ATM-activated p53-14-3-3-σ pathways, which could be reversed by ATM siRNA [4]. in vivo: Efficacy of CuB was tested in vivo using two different orthotopic models of breast cancer. MDA-MB-231 and 4T-1 cells were injected orthotopically in the mammary fat pad of female athymic nude mice or BALB/c mice respectively. Our results showed that CuB administration inhibited MDA-MB-231 orthotopic tumors by 55%, and 4T-1 tumors by 40%. The 4T-1 cells represent stage IV breast cancer and form very aggressive tumors [3].
References:
[1]. Shang Y, et al. Cucurbitacin-B inhibits neuroblastoma cell proliferation through up-regulation of PTEN. Eur Rev Med Pharmacol Sci. 2014;18(21):3297-303.
[2]. Zhang M, et al. Cucurbitacin B inhibits proliferation and induces apoptosis via STAT3 pathway inhibition in A549 lung cancer cells. Mol Med Rep. 2014 Dec;10(6):2905-11.
[3]. Gupta P, et al. Inhibition of Integrin-HER2 signaling by Cucurbitacin B leads to in vitro and in vivo breast tumor growth suppression. Oncotarget. 2014 Apr 15;5(7):1812-28.
[4]. Guo J, et al. Cucurbitacin B induced ATM-mediated DNA damage causes G2/M cell cycle arrest in a ROS-dependent manner. PLoS One. 2014 Feb 4;9(2):e88140.
- Norarecoline hydrochloride
Catalog No.:BCN8401
CAS No.:6197-39-3
- 9-Hydroxythymol
Catalog No.:BCN7979
CAS No.:61955-76-8
- Deoxyisocalyciphylline B
Catalog No.:BCN4146
CAS No.:619326-75-9
- Deoxycalyciphylline B
Catalog No.:BCN4145
CAS No.:619326-74-8
- Boc-Cys(pMeBzl)-OH
Catalog No.:BCC3377
CAS No.:61925-77-7
- Tomatidine hydrochloride
Catalog No.:BCN2861
CAS No.:6192-62-7
- Dihydroergotamine mesylate
Catalog No.:BCC5224
CAS No.:6190-39-2
- Sceleratine
Catalog No.:BCN2126
CAS No.:6190-25-6
- 4-Nitrocinnamic acid
Catalog No.:BCN5033
CAS No.:619-89-6
- p-Ethoxybenzoic acid
Catalog No.:BCN3378
CAS No.:619-86-3
- 4-Hydroxybenzamide
Catalog No.:BCN4147
CAS No.:619-57-8
- 3-(1,1-Dimethylallyl)-8-hydroxy-7-methoxycoumarin
Catalog No.:BCN7570
CAS No.:61899-42-1
- Adrenalone HCl
Catalog No.:BCC4323
CAS No.:62-13-5
- Dopamine hydrochloride
Catalog No.:BCN2195
CAS No.:62-31-7
- Phenacetin
Catalog No.:BCC4436
CAS No.:62-44-2
- Lipoic acid
Catalog No.:BCN5980
CAS No.:62-46-4
- H-Aib-OH
Catalog No.:BCC3207
CAS No.:62-57-7
- Cevadine acetate
Catalog No.:BCC8144
CAS No.:63982-55-8
- Nandrolone phenylpropionate
Catalog No.:BCC9089
CAS No.:62-90-8
- Diphemanil Methylsulfate
Catalog No.:BCC3767
CAS No.:62-97-5
- 5-Methyl-2-furaldehyde
Catalog No.:BCN3801
CAS No.:620-02-0
- Tribenzylamine
Catalog No.:BCN1817
CAS No.:620-40-6
- Hyoscyamine sulfate hydrate
Catalog No.:BCN2846
CAS No.:620-61-1
- 4,4'-Methylenediphenol
Catalog No.:BCN2690
CAS No.:620-92-8
Cucurbitacin B inhibits proliferation and induces apoptosis via STAT3 pathway inhibition in A549 lung cancer cells.[Pubmed:25242136]
Mol Med Rep. 2014 Dec;10(6):2905-11.
Natural products are a great source of cancer chemotherapeutic agents. The present study was conducted to investigate whether Cucurbitacin B (CuB), one of the most potent and widely used cucurbitacins, inhibits proliferation and induces apoptosis in the A549 lung cancer cell line. Furthermore, CuB induced apoptosis of A549 cells in a -concentration-dependent manner, as determined by fluorescence microscopy, flow cytometry and transmission electron microscopy. The present study also demonstrated that CuB dose-dependently inhibited lung cancer cell proliferation, with cell cycle inhibition and cyclin B1 downregulation. Apoptosis induced by CuB was shown to be associated with cytochrome c release, B-cell lymphoma 2 downregulation and signal transducer and activator of transcription 3 pathway inhibition. CuB may prove to be a useful approach for the chemotherapy of lung cancer.
VASP activation via the Galpha13/RhoA/PKA pathway mediates cucurbitacin-B-induced actin aggregation and cofilin-actin rod formation.[Pubmed:24691407]
PLoS One. 2014 Apr 1;9(4):e93547.
Cucurbitacin B (CuB), a potent antineoplastic agent of cucurbitacin triterpenoids, induces rapid disruption of actin cytoskeleton and aberrant cell cycle inhibiting carcinogenesis. However, the underlying molecular mechanism of such anticancer effects remains incompletely understood. In this study, we showed that CuB treatment rapidly induced vasodilator-stimulated phosphoprotein (VASP) phosphorylation (i.e. activation) at the Ser157 residue and generated VASP clumps which were co-localized with amorphous actin aggregates prior to the formation of highly-ordered cofilin-actin rods in melanoma cells. Knockdown of VASP or inhibition of VASP activation using PKA-specific inhibitor H89 suppressed CuB-induced VASP activation, actin aggregation and cofilin-actin rod formation. The VASP activation was mediated by cAMP-independent PKA activation as CuB decreased the levels of cAMP while MDL12330A, an inhibitor of adenylyl cyclase, had weak effect on VASP activation. Knockdown of either Galpha13 or RhoA not only suppressed VASP activation, but also ameliorated CuB-induced actin aggregation and abrogated cofilin-actin rod formation. Collectively, our studies highlighted that the CuB-induced actin aggregation and cofilin-actin rod formation was mediated via the Galpha13/RhoA/PKA/VASP pathway.
Cucurbitacin-B inhibits neuroblastoma cell proliferation through up-regulation of PTEN.[Pubmed:25487942]
Eur Rev Med Pharmacol Sci. 2014;18(21):3297-303.
OBJECTIVE: Cucurbitacins belong to a class of highly oxidized tetracyclic triterpenoids. Recent studies suggest that the use of Cucurbitacin could repress cancer cell progression. However, the biological effect of Cucurbitacin-B in neuroblastoma cells remains unexplored. MATERIALS AND METHODS: MTT and BrdU (bromodeoxyuridine) incorporation assays were used to determine the anti-proliferation roles of Cucurbitacin-B. Real-time PCR and Western blot assays were used to detect the expression of cell cycle regulators. Small interfering RNAs (siRNAs) were used to silence the expression of PTEN (phosphatase and tensin homolog gene). RESULTS: We found that Cucurbitacin-B inhibited growth and modulated expression of cell-cycle regulators in SHSY5Y cells. At the molecular level, we found that Cucurbitacin-B inhibited AKT signaling activation through up-regulation of PTEN. Indeed, PTEN deficiency using siRNA oligos attenuated the anti-proliferative roles of Cucurbitacin-B. CONCLUSIONS: These results provide evidence for a mechanism that may contribute to the antineoplastic effects of Cucurbitacin-B in neuroblastoma.
Cucurbitacin B regulates immature myeloid cell differentiation and enhances antitumor immunity in patients with lung cancer.[Pubmed:22746287]
Cancer Biother Radiopharm. 2012 Oct;27(8):495-503.
The aberrant activation of the JAK2/STAT3 signaling in immature myeloid dendritic cells (DCs) is associated with immune tolerance and poor antitumor immunity. The objective of this study was to test the hypothesis that Cucurbitacin B (CuB), a selective inhibitor of JAK2/STAT3 signaling, could promote DC differentiation and improve antitumor immunity. Twelve patients with advanced lung cancers were treated orally with CuB daily for 7 consecutive days. The frequency of peripheral blood myeloid DCs and immature myeloid cells (imCs) in those patients and healthy controls was characterized longitudinally by flow cytometry. The effect of CuB on the differentiation of DCs and p53-specific T responses was evaluated in vitro. The percentages of Lin(-)DR(-)CD33(+) imCs and Lin(-)DR(+)CD33(+) DCs were significantly different between patients with lung cancers and healthy controls (1.55% vs. 0.82%, p=0.002; 0.60% vs. 1.90%, p=0.000). Treatment with CuB significantly increased the frequency of Lin(-)DR(+)CD33(+), but reduced the frequency of Lin(-)DR(-)CD33(+) in patients with lung cancers (p<0.05). Treatment with CuB induced the differentiation of DCs cocultured with tumor cells 16HBE/BPDE and enhanced the sensitivity of 16HBE/BPDE cells to p53-specific CTL by inhibiting the JAK2/STAT3 activation, but also enhancing the interferon-gamma-related STAT1 activation in 16HBE/BPDE cells. CuB significantly reduced the frequency of imCs in patients with lung cancers and enhanced the effect of p53-specific CTL on tumor 16HBE/BPDE cells.
Cucurbitacin B inhibits the translational expression of hypoxia-inducible factor-1alpha.[Pubmed:24333213]
Eur J Pharmacol. 2014 Jan 15;723:46-54.
Cucurbitacin B is a triterpenoid compound isolated from Trichosanthes kirilowii Maximowicz, which has been used in oriental medicine for its antitumor activities. However, the mechanisms by which Cucurbitacin B inhibits tumor growth are not fully understood. We here demonstrated the effect of Cucurbitacin B on hypoxia-inducible factor-1 (HIF-1) activation. Cucurbitacin B showed the potent inhibitory activity against HIF-1 activation induced by hypoxia in various human cancer cell lines. This compound markedly decreased the hypoxia-induced accumulation of HIF-1alpha protein dose-dependently, whereas it did not affect the expressions of HIF-1beta. Further analysis revealed that Cucurbitacin B inhibited HIF-1alpha protein synthesis, without affecting the expression level of HIF-1alpha mRNA or degradation of HIF-1alpha protein. Rather, we found that suppression of HIF-1alpha accumulation by Cucurbitacin B correlated with strong dephosphorylation of mammalian target of rapamycin (mTOR) and its effectors ribosomal protein S6 kinase (p70S6K) and eukaryotic initiation factor 4E-binding protein-1 (4E-BP1) and extracellular signal-regulated kinase-1/2 (ERK1/2), a pathway known to regulate HIF-1alpha expression at the translational level. Cucurbitacin B also activated Akt, a mechanistic feature exhibited by established mTOR inhibitors in many tumor cells. Furthermore, Cucurbitacin B prevented hypoxia-induced expression of HIF-1 target genes and suppresses the invasiveness of tumor cells. In vivo studies further confirmed the inhibitory effect of Cucurbitacin B on the expression of HIF-1alpha proteins, leading to a decrease growth of HeLa cells in a xenograft tumor model. These results show that Cucurbitacin B is an effective inhibitor of HIF-1 and provide new perspectives into the mechanism of its anticancer activity.
